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The penetration of a new quinolone (BAY Y 3118) into human polymorphonuclear leukocytes (PMNs) was
evaluated by a fluorometric assay. The cellular concentration-to-extracellular concentration (C/E) ratio was
higher than 6.3 at extracellular concentrations ranging from 2 to 100 mg/liter. The uptake of BAY Y 3118 was
rapid, reversible and nonsaturable. The intracellular penetration of BAY Y 3118 was significantly affected by
environmental temperature (C/E ratio at 4°C, 5.4 ± 0.5; control, 7.5 ± 0.9; P < 0.05) and cell viability (C/E
ratio in dead PMNs, 5.5 ± 0.8; control, 7.5 ± 0.9; P < 0.05), but it was not affected by metabolic inhibitors. The
ingestion of opsonized zymosan or opsonized Staphylococcus aureus significantly decreased the levels of
PMN-associated BAY Y 3118. Cell stimulation by a membrane activator, however, significantly increased the
intracellular concentration of this quinolone. At therapeutic extracellular concentrations (0.5, 2, and 5
mg/liter), BAY Y 3118 showed intracellular activity greater than that of ciprofloxacin against S. aureus in
human PMNs. It was concluded that BAY Y 3118 reaches high intracellular concentrations within human
PMNs and remains active intracellularly.
The entry of antimicrobial agents into phagocytic cells is
essential for activity against intracellular microorganisms. The
use of antimicrobial agents that reach high intracellular con-
centrations and remain active within phagocytes could be
important in the therapy of infections caused by facultative
intracellular bacteria (2).
Most of the new quinolones are able to penetrate and reach
high intracellular concentrations in different phagocytic cells.
Among them, norfloxacin, ciprofloxacin, ofloxacin, and levo-
floxacin have been shown to be effective against typical facul-
tative intracellular pathogens, such as mycobacteria or Legio-
nella spp., and against other bacteria, such as Staphylococcus
aureus, that in certain circumstances are able to survive within
phagocytic cells (4, 5, 10).
BAY Y 3118 is a new chlorofluoroquinolone with antibac-
terial activity against an expanded spectrum, including gram-
positive cocci and anaerobic bacteria (14). It was found to be
more active than ciprofloxacin against S. aureus, including
ciprofloxacin-resistant and methicillin-resistant species (1).
The purpose of this study was to evaluate the uptake of BAY
Y 3118 by human polymorphonuclear leukocytes (PMNs). The
mechanism involved in the penetration of these agents into
human PMNs and its intracellular activity against S. aureus
compared with that of ciprofloxacin were also evaluated.
MATERIALS AND METHODS
Isolation of PMNs. PMNs were recovered from heparinized
venous blood of healthy donors and purified by previously
described methods (13). PMN preparations were 97% pure.
Final cell suspensions were adjusted to 5 x 106 PMNs per ml
in Hanks balanced salt solution. PMNs were 95% viable by
trypan blue exclusion.
BAY Y 3118 uptake by PMNs. A previously described
fluorometric assay was used to measure quinolone uptake by
human PMNs (9). BAY Y 3118 and ciprofloxacin were kindly
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supplied by Bayer A.G., Leverkusen, Germany. In these ex-
periments, PMNs were incubated in Hanks balanced salt
solution containing different concentrations of antimicrobial
agent (2 to 100 mg/liter). After different incubation times at
37°C, cells were separated from extracellular solution by
centrifugation through a water-impermeable silicone-oil bar-
rier in a microcentrifuge tube. The entire cell pellet, obtained
by cutting off the portion of the microcentrifuge tube contain-
ing the pellet, was placed in 2 ml of 0.1 M glycine-HCl buffer
(pH 3.0) and agitated vigorously in a vortex shaker. Incubation
for 2 h at room temperature was sufficient to release the
intracellular antimicrobial agent fully (9). Samples were cen-
trifuged for 5 min at 5,600 x g, and the amount of antimicro-
bial agent was determined by fluorescence emission of super-
natants with an F 2000 fluorescence spectrophotometer
(Hitachi, Tokyo, Japan). The fluorescence excitation and emis-
sion maxima in 0.1 M glycine-HCl (pH 3.0) were 285 and 459
nm, respectively. Controls without antimicrobial agents were
always used to determine the background fluorescence.
Intracellular water space was measured by using triated
water and the extracellular marker [14C]polyethylene glycol
(1.4 mCi/g; New England Nuclear Corp., Boston, Mass.). Cells
were incubated with these radiolabeled compounds for 2 min
at 37°C, separated from extracellular fluid by velocity gradient
centrifugation as described above, and counted in a liquid
scintillation counter. Total water content of the cell pellet was
corrected for trapped extracellular water, i.e., polyethylene
glycol space, to obtain the intracellular water space. From the
values obtained by this procedure, cell-associated antimicro-
bial agent concentrations were calculated and expressed as
ratios of the cellular concentration to extracellular concentra-
tion (C/E ratios) (7).
Characterization of BAY Y 3118 uptake. Further studies to
elucidate the mechanism of BAY Y 3118 uptake of PMNs
were performed as described previously (9). The importance of
cell viability was studied by using PMNs killed by exposure to
10% Formalin for 30 min. These cells were washed and then
suspended in fresh medium. Moreover, the influences of
environmental temperature, pH, and metabolic inhibitors were
evaluated. The influencc of temperature was examined by
2426
Vol. 38, No. 10
 on A








































0 5 10 20 25 30 40
t (min)
FIG. 1. BAY Y 3118 uptake by human PMNs and efflux of PMN-associated BAY Y 31118 after the removal of the extracellular drug (n = 5).
The extracellular concentration was 2 mg/liter. Error bars indicate standard deviations.
comparing antimicrobial uptake at 4 and 37°C. The pH profiles
of BAY Y 3118 uptake in media preadjusted to different
external pHs (pH 5, 6, 7, and 8) by the addition of 10 N HCl or
10 N NaOH were measured. An inhibitor of glycolysis (sodium
fluoride, 1.5 x 10-3 M) (Sigma Chemical Co., St. Louis, Mo.),
an inhibitor of mitochondrial oxidative metabolism (sodium
cyanide, 1.5 x 10-3 M) (Sigma), a blocker of the proton
gradient (carbonyl cyanide m-chlorophenylhydrazone, 1.5 x
10-' M) (Sigma), and an uncoupler of oxidative phosphoryla-
tion (2,4-dinitrophenol, 1 x 10-' M) (Sigma) were used as
metabolic inhibitors. PMNs in Hanks balanced salt solution
with and without metabolic inhibitors were incubated for 30
min at 37°C. BAY Y 3118 (final concentration, 2 mg/liter) was
then added, and the uptake was measured as described above.
In a series of experiments, BAY Y 3118 (extracellular
concentration, 2 mg/liter) uptake by human PMNs was mea-
sured after the stimulation of cells with 200 nM phorbol
myristate acetate (PMA; Sigma) and after the phagocytosis of
either opsonized zymosan (0.9 mg/liter; Sigma) or S. aureus
ATCC 25923 opsonized in 5% pooled human serum (15 min,
37°C) at a 10/1 ratio of bacteria to PMNs. PMA or opsonized
particles were added to PMN suspensions at the same time as
the antimicrobial agent, and the uptake was measured as
described above.
The effiux or reversibility of the binding of PMN-associated
BAY Y 3118 was also studied. PMNs were incubated for 10
min at 37°C with BAY Y 3118 (extracellular concentration, 2
mg/liter), collected by centrifugation, and rapidly suspended in
quinolone-free medium. PMN-associated BAY Y 3118 was
quantitated at various time intervals (5, 10, and 20 min) after
the removal of the extracellular antimicrobial agent. Controls
were always used to evaluate the effects of inhibitors and
substrates on the fluorescence of BAY Y 3118 in cell-free
systems.
Organisms and susceptibility testing. S. aureus ATCC 25923
was used for killing assays. Susceptibility studies were deter-
mined by dilution assay. The MICs and MBCs of ciprofloxacin
and BAY Y 3118 against this strain were 0.25 and 0.5 mg/liter
and 0.03 and 0.06 mg/liter, respectively.
Intracellular activity of quinolones. To evaluate the intra-
cellular activities of antimicrobial agents, a previously de-
scribed method was used (12). Briefly, 0.1 ml of opsonized
bacterial suspension (5 x 107 CFU/ml) and 0.1 ml of PMNs
(5 x 106 PMNs per ml) in Hanks balanced salt solution were
combined in a series of polypropylene biovials (Beckman
Instruments, Inc., Fullerton, Calif.) and incubated in a shaker
(50 rpm) for 60 min at 37°C. After incubation, extracellular
bacteria were removed by differential centrifugation. Cells
were then suspended in 0.2 ml of RPMI medium (GIBCO,
Middlesex, United Kingdom). At that time (designated time
zero), different antimicrobial agents were added and vials were
incubated in a shaker (50 rpm) at 37°C. Vials were removed at
time zero (control) and after 3 h of incubation (control and
samples with antimicrobial agents). Extracellular antimicrobial
agents were removed by washing cells with ice-cold phosphate-
buffered saline. Cells were lysed in distilled water, and samples
were diluted and pour plated on agar. Colonies were counted
after 24 h of incubation at 37°C. Data were expressed as
percentages of surviving staphylococci compared with controls
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FIG. 2. BAY Y 3118 uptake by human PMNs at different extracel-
lular concentrations (n = S). Incubations were carried out for 20 min.
Effor bars indicate standard deviations.
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TABLE 1. Effects of cell viability, environment temperature, and
pH on the intracellular penetration of BAY Y 3118
in human PMNs (n = 6)
Exptl condition(s)a C/E ratio
Viable cells at 37°C ....................... 7.5 ± 0.9
Viable cells at 4°C ....................... 5.4 + 0.5 (P = 1.30 x 10-2)b
Dead cells at 37°C ....................... 5.5 + 0.8 (P = 2.18 x 10-2)b
pH 5 ....................... 8.2 1.9
pH 6 ....................... 7.6 1.9
pH 7 ....................... 7.5 1.6
pH 8 ....................... 7.5 1.9
a Experiments were carried out for 20 min at extracellular concentrations of 2
mg/liter.
b Significant compared with viable cells at 37'C.
ing bacterial survival, morphologic studies were also routinely
performed at time zero and after 3 h of incubation to evaluate
the disposition of bacteria (cell associated or extracellular).
Samples of 50 [lI were removed from biovials and deposited on
glass slides. After being stained with Wright stain, samples
were examined by light microscopy. All assays were performed
in duplicate with PMNs from five different donors.
Statistical analysis of data. Data were expressed as means ±
standard deviations. Differences among groups were compared
by analysis of variance, which was used to assess statistical
significance at P c 0.05.
RESULTS
Uptake of BAY Y 3118 by human PMNs. The uptake and
efflux kinetics of BAY Y 3118 in human PMNs are shown in
Fig. 1. BAY Y 3118 penetrates into human PMNs rapidly,
reaching intracellular concentrations six to seven times greater
than the extracellular ones. The efflux ofBAY Y 3118 was also
rapid, with 86% of the cell-associated drug being lost within 5
min (compare values at 20 and 25 min in Fig. 1).
The effects of different extracellular concentrations on the
uptake ofBAY Y 3118 by PMNs are shown in Fig. 2. The levels
of the cell-associated drug ranged from 15.8 ± 3.2 mg/liter at
an extracellular concentration of 2 mg/liter (C/E ratio, 7.9 +
1.6) to 655 ± 75 mg/liter at an extracellular concentration of
100 mg/liter (C/E ratio, 6.7 ± 1.4).
The effects of cell viability, environmental temperature, and
pH on BAY Y 3118 uptake by human PMNs are shown in
Table 1. Intracellular penetration of BAY Y 3118 into viable
PMNs was significantly reduced at 4°C, as was the case with
dead cells, but still reached C/E ratios of greater than 5.
The effects of different metabolic inhibitors on BAY Y 3118
uptake by PMNs are shown in Table 2. Among the inhibitors
evaluated, only sodium fluoride and sodium cyanide signifi-
cantly impaired intracellular penetration of this quinolone.
TABLE 2. Effects of metabolic inhibitors on the intracellular
penetration of BAY Y 3118 in human PMNs (n = 6)a
Inhibitor C/E ratio
Control ....................... 7.5 ± 0.9
Sodium fluoride ....................... 4.3 + 2.1 (P = 4.8 x 10-2)b
Sodium cyanide ....................... 2.6 + 2.0 (P = 7.9 x 10-3)b
Carbonyl cyanide m-chlorophenyl-
hydrazone ....................... 6.3 ± 1.8
2,4-Dinitriphenol ....................... 5.3 ± 1.9
a Experiments were carried out for 20 min at extracellular concentrations of 2
mg/liter.
b Significant compared with control.
TABLE 3. Effects of cell membrane-stimulating agents on the
intracellular penetration of BAY Y 3118 in human PMNs (n = 6)a
Stimulus C/E ratio
Control............. 6.9 ± 2.3
Opsonized S. aureus............. 4.4 ± 1.3 (P = 0.025)b
Opsonized zymosan ............. 3.6 ± 1.4 (P = 1.91 x 10-1)b
PMA............. 16.6 +8.2 (P = 1.22 x 10-2)b
a Experiments were carried out for 20 min at extracellular concentrations of 2
mg/liter.
b Significant compared with control.
Finally, we evaluated the influence of phagocytosis and cell
membrane stimuli on the uptake of BAY Y 3118. We found
that the ingestion of opsonized particles such as zymosan or
bacteria significantly reduced the uptake of BAY Y 3118
PMNs (Table 3). Stimulation with PMA, however, significantly
increased intracellular concentrations of this drug.
Intracellular activity of BAY Y 3118. The intracellular
activity ofBAY Y 3118 against S. aureus compared with that of
ciprofloxacin was evaluated by a 3-h assay (Fig. 3). At each of
three extracellular concentrations, the intracellular activity of
BAY Y 3118 in human PMNs was significantly greater than
that of ciprofloxacin.
DISCUSSION
In this study, the uptake of BAY Y 3118 by human PMNs
was evaluated. Using a fluorometric assay, we observed that
this antimicrobial agent was highly concentrated in these
phagocytic cells even at therapeutical concentrations. The C/E
ratios of BAY Y 3118 were similar to those observed for
ciprofloxacin, ofloxacin, sparfloxacin, and other quinolones (3,
9-11).
The uptake of BAY Y 3118 of PMNs was rapid, nonsat-
urable (at extracellular concentrations of between 2 and 200
mg/liter), and reversible. The intracellular penetration of BAY
Y 3118 was affected by cell viability, environmental tempera-
ture, and some metabolic inhibitors (sodium fluoride and
sodium cyanide). It is interesting that even an inhibitor of
mitochondrial oxidative metabolism, such as sodium cyanide,
decreased the uptake of ofloxacin by PMNs since these cells
have few mitochondria and do not depend upon oxidative








FIG. 3. Effects of BAY Y 3118 (solid bars) and ciprofloxacin
(hatched bars) on the killing of S. aureus ATCC 25923 ingested by
human PMNs. Data are expressed as percentages of the levels in
controls (without antimicrobial agents) (n = 5). *, P < 0.05 when
compared with ciprofloxacin. Error bars indicate standard deviations.
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to a secondary or minor activity of this inhibitor in other meta-
bolic functions of phagocytes. Similar results have previously been
described for ofloxacin and levofloxacin (10). The uptake of other
quinolones, such as sparfloxacin, by human PMNs was not
affected by any of these parameters (3). Lomefloxacin penetration
and temafloxacin penetration into human PMNs, however, were
affected by environmental temperature (11). These data indicate
that more than one mechanism may mediate the intracellular
penetration of different quinolones.
The penetration of BAY Y 3118 decreased slightly when
PMNs were incubated with opsonized zymosan or S. aureus.
The stimulation of PMN membranes by PMA, an activator of
the NADPH oxidase system via protein kinase C (8), signifi-
cantly increased the uptake of this quinolone by human PMNs.
This divergent effect could be related to the fact that the
activation of NADPH oxidase by opsonized particles differs
from that of PMA, the former being mediated by phospho-
lipase A2 (8). The mechanism whereby BAY Y 3118 accumu-
lates in cells is not yet known, and no simple model can be
presented in view of the findings presented above. Although
certain data point to a passive mechanism, as has been
postulated for sparfloxacin (3), many others are typical of an
active mechanism, as has been described for ofloxacin and
levofloxacin (10). Our previous experiences show that although
most quinolones reach similar intracellular concentrations in
phagocytic cells, different mechanisms may be involved. These
mechanisms do not seem to be related either to the degree of
fluorination of the molecule (11) or to the partition coefficients
(3), as has been previously demonstrated.
A contrast between phagocyte antimicrobial agent uptake
and intracellular activity has been described for a few antimi-
crobial agents (6). In our study, BAY Y 3118 showed intra-
cellular activity against S. aureus. In fact, this activity was
significantly greater than those of ciprofloxacin and other
quinolones previously evaluated (10, 11); this effect was par-
tially due to the higher bactericidal activity of this antimicro-
bial agent against the strain evaluated.
In summary, BAY Y 3118 penetrates into human PMNs,
reaching intracellular concentrations several times greater
than the extracellular ones while remaining active intracellu-
larly. The high antimicrobial activity of this quinolone in
addition to the properties observed in this study enhances the
potential uses of BAY Y 3118.
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